136 related articles for article (PubMed ID: 31938317)
1. Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma.
Yu GF; Lin X; Luo RC; Fang WY
Int J Clin Exp Pathol; 2018; 11(4):2092-2099. PubMed ID: 31938317
[TBL] [Abstract][Full Text] [Related]
2. Low MYH9 expression predicts a good prognosis for hepatocellular carcinoma.
Lin X; Yu GF; Zuo S; Luo RC; Fang WY
Int J Clin Exp Pathol; 2018; 11(5):2784-2791. PubMed ID: 31938396
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models.
Zhao Q; Zhou H; Liu Q; Cao Y; Wang G; Hu A; Ruan L; Wang S; Bo Q; Chen W; Hu C; Xu D; Tao F; Cao J; Ge Y; Yu Z; Li L; Wang H
Oncotarget; 2016 Jul; 7(30):47431-47443. PubMed ID: 27329727
[TBL] [Abstract][Full Text] [Related]
5. Correlation of KAI1, CD133 and vasculogenic mimicry with the prediction of metastasis and prognosis in hepatocellular carcinoma.
Xu J; Zhang Y; Wang Y; Tao X; Cheng L; Wu S; Tao Y
Int J Clin Exp Pathol; 2018; 11(7):3638-3646. PubMed ID: 31949744
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.
Chen D; Li Z; Cheng Q; Wang Y; Qian L; Gao J; Zhu JY
J Clin Pathol; 2019 Sep; 72(9):588-596. PubMed ID: 31126975
[TBL] [Abstract][Full Text] [Related]
7. Elevated GSK3β expression predicts good prognosis in hepatocellular carcinoma.
Hu Y; Lin X; Zuo S; Luo R; Fang W
Int J Clin Exp Pathol; 2018; 11(5):2776-2783. PubMed ID: 31938395
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cell marker expression alone and in combination with microvascular invasion predicts poor prognosis in patients undergoing transplantation for hepatocellular carcinoma.
Vilchez V; Turcios L; Zaytseva Y; Stewart R; Lee EY; Maynard E; Shah MB; Daily MF; Tzeng CW; Davenport D; Castellanos AL; Krohmer S; Hosein PJ; Evers BM; Gedaly R
Am J Surg; 2016 Aug; 212(2):238-45. PubMed ID: 27033253
[TBL] [Abstract][Full Text] [Related]
9. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
10. Cancer Stem Cell Markers in Eyelid Sebaceous Gland Carcinoma: High Expression of ALDH1, CD133, and ABCG2 Correlates With Poor Prognosis.
Kim N; Choung HK; Lee MJ; Khwarg SI; Kim JE
Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1813-9. PubMed ID: 25711631
[TBL] [Abstract][Full Text] [Related]
11. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
12. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.
Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR
Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805
[TBL] [Abstract][Full Text] [Related]
13. CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: A long-term follow-up analysis.
Dai XM; Yang SL; Zheng XM; Chen GG; Chen J; Zhang T
Oncol Lett; 2018 Mar; 15(3):2985-2991. PubMed ID: 29435028
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma.
Sung JJ; Noh SJ; Bae JS; Park HS; Jang KY; Chung MJ; Moon WS
J Pathol Transl Med; 2016 Jan; 50(1):52-7. PubMed ID: 26581206
[TBL] [Abstract][Full Text] [Related]
15. Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma.
Ma XL; Jiang M; Zhao Y; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Cao Y; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Ann Surg Oncol; 2018 Jun; 25(6):1686-1694. PubMed ID: 29626309
[TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma.
Sasaki A; Kamiyama T; Yokoo H; Nakanishi K; Kubota K; Haga H; Matsushita M; Ozaki M; Matsuno Y; Todo S
Oncol Rep; 2010 Aug; 24(2):537-46. PubMed ID: 20596644
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG
Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447
[TBL] [Abstract][Full Text] [Related]
19. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
[TBL] [Abstract][Full Text] [Related]
20. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.
Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D
Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
